A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types

KRAS- and BRAF-mutant tumors are often dependent on MAPK signaling for proliferation and survival and thus sensitive to MAPK pathway inhibitors. However, clinical studies have shown that MEK inhibitors are not uniformly effective in these cancers indicating that mutational status of these oncogenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagle, Marie-Claire, Kirouac, Daniel, Klijn, Christiaan, Liu, Bonnie, Mahajan, Shilpi, Junttila, Melissa, Moffat, John, Merchant, Mark, Huw, Ling, Wongchenko, Matthew, Okrah, Kwame, Srinivasan, Shrividhya, Mounir, Zineb, Sumiyoshi, Teiko, Haverty, Peter M., Yauch, Robert L., Yan, Yibing, Kabbarah, Omar, Hampton, Garret, Amler, Lukas, Ramanujan, Saroja, Lackner, Mark R., Huang, Shih-Min A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871852/
https://www.ncbi.nlm.nih.gov/pubmed/29872725
http://dx.doi.org/10.1038/s41698-018-0051-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871852/
https://www.ncbi.nlm.nih.gov/pubmed/29872725
http://dx.doi.org/10.1038/s41698-018-0051-4

Ejemplares similares